High‐throughput identification of conditional MHCI ligands and scaled‐up production of conditional MHCI complexes

Nanolipoprotein Particles as a Delivery Platform for Fab Based Therapeutics

(2020) Martine Darwish et al.   BIOCONJUGATE CHEMISTRY

High-throughput peptide-MHC complex generation and kinetic screenings of TCRs with peptide-receptive HLA-A*02:01 molecules

(2019) Andreas Moritz et al.   Science Immunology

Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells

(2019) Sunil Kumar Saini et al.   Science Immunology

A flexible MHC class I multimer loading system for large-scale detection of antigen-specific T cells

(2018) Jolien J. Luimstra et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Hitting the Target: How T Cells Detect and Eliminate Tumors

(2018) Anthony E. Zamora et al.   JOURNAL OF IMMUNOLOGY

Prospects of IL-2 in Cancer Immunotherapy

(2018) Hani Choudhry et al.   Biomed Research International

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient

(2016) Aude G. Chapuis et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Design and validation of conditional ligands for HLA-B*08:01, HLA-B*15:01, HLA-B*35:01, and HLA-B*44:05

(2015) Thomas Mørch Frøsig et al.   CYTOMETRY PART A

Cish actively silences TCR signaling in CD8 + T cells to maintain tumor tolerance

(2015) Douglas C. Palmer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Immune modulation for cancer therapy

(2014) J Naidoo et al.   BRITISH JOURNAL OF CANCER

Trafficking of T Cells into Tumors

(2014) C. Y. Slaney et al.   CANCER RESEARCH

Entering the mainstream of cancer treatment

(2014) Steven A. Rosenberg   Nature Reviews Clinical Oncology

T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy

(2014) I. Melero et al.   Cancer Discovery

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

(2013) Amy E Moran et al.   CURRENT OPINION IN IMMUNOLOGY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

(2013) Nienke van Rooij et al.   JOURNAL OF CLINICAL ONCOLOGY

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

(2013) Paul F Robbins et al.   NATURE MEDICINE

Dipeptides promote folding and peptide binding of MHC class I molecules

(2013) S. K. Saini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity

(2012) Mikkel Harndahl et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Conditional ligands for Asian HLA variants facilitate the definition of CD8+T-cell responses in acute and chronic viral diseases

(2012) Cynthia X. L. Chang et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Porcine major histocompatibility complex (MHC) class I molecules and analysis of their peptide-binding specificities

(2011) Lasse Eggers Pedersen et al.   IMMUNOGENETICS

An Early HIV Mutation within an HLA-B*57-Restricted T Cell Epitope Abrogates Binding to the Killer Inhibitory Receptor 3DL1

(2011) S. Brackenridge et al.   JOURNAL OF VIROLOGY

MHC–peptide tetramers for the analysis of antigen-specific T cells

(2010) Stuart Sims et al.   Expert Review of Vaccines

Modification of MHC Anchor Residues Generates Heteroclitic Peptides That Alter TCR Binding and T Cell Recognition

(2010) D. K. Cole et al.   JOURNAL OF IMMUNOLOGY

Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7

(2008) A. H. Bakker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA